EA200700380A1 - Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения - Google Patents

Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения

Info

Publication number
EA200700380A1
EA200700380A1 EA200700380A EA200700380A EA200700380A1 EA 200700380 A1 EA200700380 A1 EA 200700380A1 EA 200700380 A EA200700380 A EA 200700380A EA 200700380 A EA200700380 A EA 200700380A EA 200700380 A1 EA200700380 A1 EA 200700380A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
growth hormone
human growth
glycerolicolorbed
conjugates
Prior art date
Application number
EA200700380A
Other languages
English (en)
Inventor
Рори Ф. Финн
Нед Р. Сиджел
Original Assignee
Фармация Энд Апджон Компани Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200700380(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармация Энд Апджон Компани Ллс filed Critical Фармация Энд Апджон Компани Ллс
Publication of EA200700380A1 publication Critical patent/EA200700380A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Настоящее изобретение относится к ПЭГилированию гормона роста человека (hGH) с использованием глицеринразветвленного ПЭГ. Настоящее изобретение также относится к способам ПЭГилирования hGH. Кроме того, настоящее изобретение относится к фармацевтическим композициям, включающим ПЭГилированный hGH. Еще один вариант осуществления включает использование ПЭГилированного hGH для лечения нарушений роста и развития.
EA200700380A 2004-08-31 2005-08-25 Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения EA200700380A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31
PCT/IB2005/002939 WO2006024953A2 (en) 2004-08-31 2005-08-25 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof

Publications (1)

Publication Number Publication Date
EA200700380A1 true EA200700380A1 (ru) 2007-10-26

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700380A EA200700380A1 (ru) 2004-08-31 2005-08-25 Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения

Country Status (24)

Country Link
EP (1) EP1789092A2 (ru)
JP (1) JP2008511610A (ru)
KR (1) KR20070042567A (ru)
CN (1) CN101010105A (ru)
AP (1) AP2007003919A0 (ru)
AR (1) AR050851A1 (ru)
AU (1) AU2005278903A1 (ru)
BR (1) BRPI0515118A (ru)
CA (1) CA2577999A1 (ru)
CR (1) CR8942A (ru)
EA (1) EA200700380A1 (ru)
EC (1) ECSP077281A (ru)
GT (1) GT200500235A (ru)
IL (1) IL181085A0 (ru)
MA (1) MA28908B1 (ru)
MX (1) MX2007002441A (ru)
NL (1) NL1029828C2 (ru)
NO (1) NO20071322L (ru)
PE (1) PE20060654A1 (ru)
TN (1) TNSN07078A1 (ru)
TW (1) TW200621291A (ru)
UY (1) UY29088A1 (ru)
WO (1) WO2006024953A2 (ru)
ZA (1) ZA200701802B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751898B2 (en) 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
AU775937B2 (en) 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US20090117077A1 (en) * 2006-05-12 2009-05-07 Dong-A Pharm. Co., Ltd. Polyethylene glycol-interferon alpha conjugate
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
KR101079993B1 (ko) * 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
RU2483081C2 (ru) * 2008-07-23 2013-05-27 Ханми Сайенс Ко.,Лтд.,Kr Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
UA104146C2 (ru) 2008-07-31 2014-01-10 Фармаиссеншиа Корп. ПОЛИМЕРНЫЕ КОНЪЮГАТЫ ФРАГМЕНТОВ ИНТЕРФЕРОНА-β, ЭРИТРОПОЭТИНА И ГОРМОНА РОСТА
SI2340271T1 (sl) * 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Konjugati polimer-bioaktivnega sredstva
KR101726715B1 (ko) * 2008-10-10 2017-04-13 폴리액티바 피티와이 리미티드 생분해성 폴리머-생물활성 모이어티 공액체
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
CN101831067A (zh) * 2010-05-31 2010-09-15 王二新 聚乙二醇脂类缀合物及其在制备药物中的应用
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (zh) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 链官能化的多级支化聚乙二醇及其合成方法
DK2947111T3 (en) * 2013-01-17 2018-05-07 Xiamen Sinopeg Biotech Co Ltd MONOFUNCTIONAL BRANCHED POLYETHYLENE LYCOL AND BIORELATED SUBSTANCE MODIFIED BY SAME
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
ES2966888T3 (es) 2014-11-06 2024-04-24 Pharmaessentia Corp Régimen de dosificación para el interferón pegilado
CN111801120A (zh) 2017-12-29 2020-10-20 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
EP3731871B1 (en) * 2017-12-29 2023-10-04 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
JP7227633B2 (ja) * 2017-12-29 2023-02-22 エフ． ホフマン－ラ ロシュ エージー． Ｐｅｇ化タンパク質組成物を提供するための方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (ja) * 1996-11-05 2000-09-25 日本油脂株式会社 コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
AU751898B2 (en) * 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
JP3921781B2 (ja) * 1998-02-12 2007-05-30 日本油脂株式会社 カルボキシル基含有ポリオキシアルキレン化合物
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CN1608079A (zh) * 2001-11-20 2005-04-20 法玛西雅公司 化学修饰的人生长激素缀合物
NZ538624A (en) * 2002-09-09 2007-01-26 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
JP4412461B2 (ja) * 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
JP4975966B2 (ja) * 2002-12-31 2012-07-11 ネクター セラピューティクス ケトンまたは関連する官能基を含むポリマー試薬
WO2005000360A2 (en) * 2003-05-23 2005-01-06 Nektar Therapeutics Al, Corporation Peg derivatives having an amidocarbonate linkage

Also Published As

Publication number Publication date
EP1789092A2 (en) 2007-05-30
TW200621291A (en) 2006-07-01
NO20071322L (no) 2007-05-29
AU2005278903A1 (en) 2006-03-09
IL181085A0 (en) 2007-07-04
AP2007003919A0 (en) 2007-02-28
CN101010105A (zh) 2007-08-01
UY29088A1 (es) 2006-03-31
NL1029828A1 (nl) 2006-03-01
TNSN07078A1 (fr) 2008-06-02
CA2577999A1 (en) 2006-03-09
GT200500235A (es) 2006-03-21
PE20060654A1 (es) 2006-08-12
ZA200701802B (en) 2008-08-27
MA28908B1 (fr) 2007-10-01
JP2008511610A (ja) 2008-04-17
AR050851A1 (es) 2006-11-29
MX2007002441A (es) 2007-05-04
ECSP077281A (es) 2007-03-29
WO2006024953A2 (en) 2006-03-09
NL1029828C2 (nl) 2006-10-20
WO2006024953A3 (en) 2007-01-18
BRPI0515118A (pt) 2008-07-01
KR20070042567A (ko) 2007-04-23
CR8942A (es) 2007-08-16

Similar Documents

Publication Publication Date Title
EA200700380A1 (ru) Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения
EA200602137A1 (ru) Гидрогелевые препараты интерферона
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
BRPI0317376B8 (pt) proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
BRPI0406605B8 (pt) conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
BRPI0813699A2 (pt) Formulações de proteína de fusão glp-1-fc
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
DK1715887T3 (da) N-terminalt monopegyleret humant væksthormonkonjugater, fremgangsmåde til deres fremstilling og anvendelsen deraf
DE602005002653D1 (de) Stabilisierte zusammensetzungen mit einem therapeutischen wirkstoff; zitronensäure oder einer konjugierten base und chlordioxid
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
TW200833367A (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
WO2007050121A3 (en) Site specific pegylated hemoglobin, method of preparing same, and uses thereof
EA200701072A1 (ru) Препараты бензотиазола и их применение
WO2007134118A3 (en) Protein based composition and methods of using same
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DK1537132T3 (da) Salt af mortin-6-glucuronid